Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis
Authors:
- 15 October 2007
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 179 (8) , 5126-5136
Abstract
Negative immunoregulation is a major barrier to successful cancer immunotherapy. The NKT cell is known to be one such regulator. In this study we explored the roles of and interaction between the classical type I NKT cell and the poorly understood type II NKT cell in the regulation of tumor immunity. Selective stimulation of type II NKT cells suppressed immunosurveillance, whereas stimulation of type I NKT cells protected against tumor growth even when responses were relatively skewed toward Th2 cytokines. When both were stimulated simultaneously, type II NKT cells appeared to suppress the activation in vitro and protective effect in vivo of type I NKT cells. In the absence of type I, suppression by type II NKT cells increased, suggesting that type I cells reduce the suppressive effect of type II NKT cells. Thus, in tumor immunity type I and type II NKT cells have opposite and counteractive roles and define a new immunoregulatory axis. Alteration of the balance between the protective type I and the suppressive type II NKT cell may be exploited for therapeutic intervention in cancer.Keywords
This publication has 47 references indexed in Scilit:
- Type II NKT cell–mediated anergy induction in type I NKT cells prevents inflammatory liver diseaseJournal of Clinical Investigation, 2007
- Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cellsJournal of Clinical Investigation, 2006
- Targeting tumor-associated macrophages as a novel strategy against breast cancerJournal of Clinical Investigation, 2006
- A nonclassical non-Vα14Jα18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillanceJournal of Experimental Medicine, 2005
- TOWARD AN UNDERSTANDING OF NKT CELL BIOLOGY: Progress and ParadoxesAnnual Review of Immunology, 2005
- Unmasking immunosurveillance against a syngeneic colon cancer by elimination of CD4+ NKT regulatory cells and IL-13International Journal of Cancer, 2004
- Activation of a Nonclassical NKT Cell Subset in a Transgenic Mouse Model of Hepatitis B Virus InfectionImmunity, 2002
- Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunityEuropean Journal of Immunology, 2001
- Differences in the Ligand Specificity between CD1d‐Restricted T Cells with Limited and Diverse T‐Cell Receptor RepertoireScandinavian Journal of Immunology, 2000
- CD1d-Restricted and TCR-Mediated Activation of V α 14 NKT Cells by GlycosylceramidesScience, 1997